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Abstract

Environmental factors, such as heavy metal exposures, have been suggested to have an impact not
only on neurodegenerative disease, such as Parkinson’s disease, but also on psychostimulants
abuse and their toxicity. In this study, two questions were addressed: 1) effects of mercuric
chloride on parkinsonian toxicant 1-methyl-4-phenylpyridinium (MPP+) induced cytotoxicity and
2) effects of mercuric chloride on cell surface dopamine transporter. Pheochromocytorma cells
(PC12) were treated with various concentrations of mercuric chloride (0.02~2.0 ppm) for 4 hours
with and without 0.1 mM MPP+. Significant potentiation of toxicity was observed when there was
co-treatment with 0.5 ppm HgCl2 and 0.1mM MPP+ vs. HgCl2 alone. The potentiation of toxicity
with the co-treatment of 0.5 ppm mercuric chloride and 0.1mM MPP+ was not observed in PC12
cells expressing DAT mutant L368Q, which has impaired uptake activity. Cell surface expression
of dopamine transporter was quantitatively seen to be transiently increased via western blot
analysis which was correspondingly visualized via immunocytochemical assay. In summary,
mercuric chloride enhanced MPP+ toxicity in a dopamine transporter-dependent manner and
increased the surface expression of dopamine transporter in PC12 cells. This toxicological effect
of mercury on dopamine transporter could trigger an unpredicted toxicological/pharmacological
interaction with drugs affecting the dopaminergic system.
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1. Introduction
Mercury (Hg) is a known ubiquitous neurotoxic metal that is able to travel through the
environment and food web while interconverting between its different chemical forms (Morel,
Kraepiel, & Amyot, 1998). Mercury species in our environment can be in various oxidation
states including mercuric (+2) and mercurous (+1). In particular, methyl mercury (MeHg)
compounds are a major contaminant in the food chain, MeHg is formed by the conversion of
inorganic mercury in the environment by microorganisms (Morel et al., 1998). MeHg can be
bioaccumulated and reach high levels especially in organisms at the top of the food chain, which
includes humans.
In humans and other animals, the body's general protective measures for eliminating
mercury from the body include elimination through the intestines (MeHg) and kidneys (inorganic
Hg) (Morel et al. 1998; Guzzi & Porta, 2008). When these measures are unable to cope with the
amount of accumulated mercury, toxicity or accumulation can occur. Direct exposure to
inorganic elemental mercury (Hg0) vapors is a concern for dental professionals and patients that
are chronically exposed to mercury containing dental amalgams (Mackert & Berglund, 1997).
Critically, internal conversion of mercury species, such as methylmercury and elemental mercury
in the body, would result in the accumulation of Hg at the brain and kidneys. Chemically, after
entering the bloodstream some of the elemental mercury diffuses into erythrocytes and is
converted to divalent mercuric cation (Aschner & Aschner, 1990). The elemental mercury that
crosses the blood brain barrier, is then oxidized by peroxide catalase from elemental mercury to
divalent mercury cation which then attaches to thiol containing ligands (Aschner & Aschner,
1990).
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It was originally thought that methylmercury crosses the blood brain barrier (BBB) due to
its lipophilic properties. In rat, methyl mercury was found to pass the BBB via the L (large
neutral) amino acid carrier as a complex with L-cysteine (MeHg-L-cysteine), which is
structurally similar to the naturally occurring amino acid methionine (Kerper, Ballatori, &
Clarkson, 1992; Morkrzan, Kerper, Ballatori, & Clarkson, 1995).This complex is formed as the
result of mercury's affinity for sulfhydryl group containing proteins (Morkrzan et al.,1995). A
study of methylmercury ingestion in macaques demonstrated accumulation of inorganic mercury
rather than methylmercury within astroglia and neurons of the brain thalamus (Charleston et al.,
1996; Charleston, Body, Mottet, Vahter, & Burbacher, 1995; Nagano, Yasutake, & Miura,
2010). Inorganic mercury is not lipophilic and thus, would not be expected to cross the BBB;
however, long term exposure has resulted in eventual detectable levels within the brain of
monkeys (Vahter et al., 1994). The travel of inorganic mercury Hg2+ past the BBB has been
proposed to occur as a result of an unidentified transporter (Castiglioni & Qian, 2001). Similar to
what was observed in the macaque study, large amounts of inorganic mercury were found in
human brain who had been exposed to high levels of methyl mercury in the Minamata mercury
disaster (Minamata bay, Japan) (Takahashi, Suetomi, & Konishi, 1991). Since the mercury
accumulated in the brain is in the form of the inert mercuric selenide and sulfide, the neurotoxic
effect of Hg2+ must occur after the demethylation of methylmercury and before the conversion to
the final inert Hg species. However, as far as our knowledge, the possible underling mechanism
is not clear.
Investigation of environmental heavy metals and toxins is of importance due to their
possible individual or combined effects on the neuronal system of the body (Andrade, Aschner,
& Marreilha dos Santos, 2017). Both exposure and accumulation of environmental heavy metals
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and toxins may lead to detrimental effects, which can worsen when combined with neurotoxins.
The link between heavy metal exposure including lead (Pb), manganese (Mn), and Mercury (Hg)
to neurodegenerative diseases including Parkinson's and Alzheimer's has been investigated
(Charlet et al., 2012). Additionally, effect on the neurons can lead to change in responsiveness or
adverse reactions when combined with drug use.
Parkinson’s disease (PD) is a neurodegenerative disease characterized by presence of αsynuclein Lewy body aggregates and degeneration of midbrain neurons in both the substantia
nigra pars compacta neurons (Kasten, Chade, & Tanner, 2007; Dauer & Przedborski, 2003) and
thalamus (Halliday, 2009), which belong to dopaminergic system (Grace, Floresco, Goto, &
Lodge, 2007; Girault & Greengard, 2004). Physical manifestations of Parkinson’s disease (PD)
are tremor at rest, bradykinesia, muscular rigidity, and postural instability (Jankovic, 2008). The
disease has been linked to both genetic and environmental sources (Jankovic, 2008), such as
mutations in the α-synuclein gene and exposure to neurotoxin 1-methyl-4-phenyl-1,2,3,6tetrahydropyridine (MPTP) (Polymeropoulos et al., 1997; Smeyne & Jackson-Lewis, 2004;
Burns, LeWitt, Ebert, & Kopin, 1985; Wichmann & DeLong, 2003). MPTP crosses the blood
brain barrier and is converted to 1-methyl-4-phenylpyridinium (MPP+) within astrocytes. MPP+
is specially taken into dopaminergic neurons through the dopamine transporter (DAT), leading
the inhibition of the mitochondrial complex I and neuronal death (Smeyne & Jackson-Lewis,
2004).
The dopaminergic system regulates reward and motor movement and consists of the
dopamine producing neurons in the brain. Neurotransmitter dopamine is released at the synapse
by vesicles and dopamine signaling is cut off by the DAT (Grace et al., 2007; Girault &
Greengard, 2004). Thus, any agent interfering dopaminergic transmission can result in disruption

4

and disorder of this system. Disrupting DAT function which results in dopamine persisting
longer in the synapses, is widely accepted as the primary cause of the reinforcing and addictive
properties of psychostimulants. Abusive drugs increase dopamine signaling by reducing the DAT
uptake activity (Drug Facts: Cocaine, 2018., Drug Facts: Methamphetamine, 2019., Li, Cheng, &
Reith, 2010; Verma, 2015). Specifically, cocaine is a DAT blocker, which inhibits dopamine
reuptake from synapse (Verma, 2015). Methamphetamine affects dopamine level in synapses in
a more complex manner as a DAT substrate to enhance internalization of DAT (Li et al., 2010;
Wallace and Hood, 2018). In animal studies heavy metal exposure has been shown to result in
alteration in sensitivity to the increase of dopamine at the synapse caused by psychostimulants
(Wallace & Hood, 2018; Jones and Miller, 2008). Specifically, lead (Pb) and manganese (Mn)
increase sensitivity of dopamine receptors leading to higher sensitivity to psychostimulants
(Jones & Miller, 2008). Cadmium (Cd) however, reduces sensitivity to psychostimulants via
reduction of dopamine turnover (Jones & Miller, 2008).
Dysfunction in the regulation of dopamine neurotransmission is involved in many
neurological diseases such as Parkinson’s and disorders including, attention hyperactivity
disorder (ADHD), bipolarism, and depression (Girault & Greengard, 2004). Exposure to toxins
and heavy metals has been linked with Parkinson's and other neurodegenerative disorders
(Charlet et al., 2012). It has been suggested that the affinity of mercury for selenoproteins results
in disruption of redoxregulation leading to oxidative stress promoting the onset of
neurodegenerative and neurological disorders (Farina, Avila, Da Rocha, & Aschner, 2013).
Mercury has been suggested to be a possible source of the neurological disorder autism (Blaxill,
Redwood, & Bernard, 2004; Mutter, Naumann, Shneider, Walach, & Haley. 2005). It has been
shown that individuals exposed to inorganic mercury exhibit memory deficits indicating
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neurological impact by mercury (Mutter, Curth, Naumann, Deth, & Walach, 2010). A biphasic
pattern of radioligand binding to DAT in the presence of HgCl2was found in membrane and
whole cell preparations (Schweri, 1994; Wu, Coffey, & Reith, 1997). It was suggested that DAT
binding was increased as a result of conformational change of DAT caused by HgCl 2. The
expression and function of DAT however, in the presence of HgCl2 was not investigated in these
samples. Wallace and Hood (2018) investigated the treatment of the combination of HgCl2 and
cocaine on the expression of human DAT on neuroblastoma cell surface and found that while
density was increased, there was no correlation with increased functionality of the DAT to
uptake dopamine (Wallace & Hood, 2018). The expression and function of DAT in the presence
of HgCl2 was not investigated. Alteration of the DAT surface expression in the dopaminergic
system could result in unexpected effects regarding sensitivity to psychostimulants drugs and
other toxins such as MPP+ that also act on the same system. Thus, the effect of Hg2+ (introduced
as mercuric chloride) on surface expression of DAT in PC12 cells was investigated in this study.
2. Materials and Methods
In order to investigate the effect of mercuric chloride on the DAT expression on the
surface of rat pheochromocytoma cells (PC12), lab grown PC12 cells was exposed to mercuric
chloride (HgCl2) solutions with various concentrations range of 0.2-2.0 ppm. Mercuric chloride
stock solution was prepared in phosphate buffered saline (PBS) and stock concentration was
determined using a DMA 80 direct mercury analyzer (Milestone, Monroe, CT). For cell viability
assessment, MTT assay was performed. Western blot analysis and biotinylation were used to
assess relative change of cell surface DAT expression levels. Visualization of distribution of
DAT on the surface of cells was done with immunocytochemistry.
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2.1 Cell culture
Rat pheochromocytoma cells (PC12) as in vitro artificial nerve system tissue model is commonly
used for neurodegeneration study. PC12 cell line used in this study was obtained from the
American Type Culture Collection (ATCC, Manassas, VA) and grown with Dulbecco’s
Modified Eagle’s Medium (DMEM) (Gibco, Grand Island, NY) supplemented with 10% fetal
bovine serum (FBS) (Gibco, Grand Island, NY), 5% heat inactivated horse serum (Biowhitaker,
Walkersville, MD), and 50 µg/mL gentamicin in a humidified incubator set at 37oC and 5% CO2.
For chemical treatment, cells were subcultured a day prior to the experiment. Cells were grown
until about ~80% confluence on the day of chemical treatments.
2.2 Chemical treatment
Cells were treated with various concentrations of HgCl2 alone (0.02-2.0ppm) or together
with 0.1 mM MPP+. Exposure time for western blot and also immunocytochemical analysis was
0.5 hour to 1 hour and for MTT assay was 4 hours. After washing, cells were analyzed with
different assays.
HgCl2 treatment solution was prepared via dilution of a master solution which had ~ 4-8
mg of mercury dissolved in Milli-Q (Millipore) ultra-pure water for total volume of 200 mL.
Secondary testing solution was prepared by adding an appropriate volume of the master solution
based on calculated concentration depending on amount of mercury used to prepare stock and
diluting it to a final volume of 5 mL. Concentration of the secondary solution was analyzed for
total mercury concentration using a Milestone direct mercury analyzer model # 80 (Sorisole,
Italy). Concentration of the stock was then back calculated from the concentration of the
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secondary solution concentration that was analyzed. Working solutions were then prepared from
the secondary stock solution based on concentration calculated and ranged from 0.02-2.0 ppm.
The MPP+ working solution was prepared fresh prior to each experiment in PBS by
making a stock solution of 0.1M concentration and adding appropriate volume of stock to obtain
the final concentration of 0.5mM in experimental well based on volume.
2.3 Cell Viability assay: MTT Assay
MTT assay is a colorimetric assay used as a quantitative indicator of cell viability. The
cellular colorimetric assay uses a yellow tetrazolium salt MTT (3-(4,5-dimethylthiazol-2-yl)-2,5diphenyl tetrazolium bromide) which is converted to a purple formazan product through cleavage
of the tetrazolium ring by active cellular mitochondria dehydrogenase enzymes (Mosmann,
1983). The amount of product formed is proportional to activity of cellular mitochondria which
is indicator of mitochondrial and thus cellular health.
MTT assay was carried out by following manufacturer’s protocol (Sigma-Aldrich,
TOX1-1KT). In brief, following exposure (4 hours) and removal of treatment chemicals, cells
were incubated (37oC, 5% CO2) for 2.5 hours with 5 mg/mL MTT (3-(4,5-dimethylthiazol-2-yl)2,5-diphenyl tetrazolium bromide) solution before MTT solubilizing solution (acidified
isopropanol) was added. Plate was then gently shaken for 1 hour at room temperature and
absorbance at 570nm and 690nm (background) was read using the Synergy Mx microplate
reader (Biotek, Winooski, Vermont).
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2.4 Western Blot Analysis
To detect the expression of DAT on surface of PC12 cells, biotinylation technique was
used. Biotinylation uses biotin to label cell surface proteins, which can then be isolated by
NeutrAvidin gel. Surface DAT can be isolated using this method together with all other cell
surface proteins. Western blot analysis will be able to detect the expression of DAT in the
isolated total cell surface proteins. Therefore, chemical treated cells were first labelled with
biotin and then western blot analysis was used to determine the level of biotinylated DAT in
order to relatively quantitate surface DAT expression after exposure to mercury (30 minutes or 1
hour).
After removal of treatment, total cell surface proteins including DAT were labeled by
biotin. In brief, cells were washed with cold phosphate buffered saline containing 1mM CaCl2
and 1mM MgCl2 (PBS-CM). Ice-cold sulfo-NHS-SS biotin reagent (1 mg/mL in PBS-CM)
(Pierce) was then added. Cultures were gently shaken at 4oC for 60 minutes, which was
followed, by washing and incubation for 20 minutes with cold PBS-CM-100 mM glycine and
PBS.
After washing with PBS, cells were then lysed and subjected for cell surface protein
isolation. In brief, cells were lysed in Mammalian Protein Extraction reagent (M-PER) / Protease
Inhibitor cocktail (PI) (Pierce) for 10 minutes at room temperature. Cell lysate was collected
through scraping and homogenized by shaking for 1 hour at 4oC. Lysate was then subjected to
centrifugation at 14,000 xg for 15 minutes. Supernatant was collected for cell surface protein
isolation. Total protein concentration was determined using the Bio-Rad DC (detergent
compatible) Protein Assay Kit (Bio-Rad Laboratories, Hercules, CA). Bovine Serum Albumin
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(Sigma) was used to set up the standard curve for protein concentration calculations. Measured
amount of total lysate proteins (250ug) was transferred to a centrifuge column (Pierce) and
incubated with NeutrAvidin gel (Thermo Scientific) for 2 hours at room temperature to isolate
biotinylated cell surface protein. NeutrAvidin gel was washed extensively with PBS, high salt
buffer (500mM NaCl / 50mM Tris pH 7.5), and no salt wash buffer (50mM Tris pH 7.5). Bound
biotinylated proteins were then removed from the NeutrAvidin gel by incubation with 50mM
dithiothreitol (DTT)/sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)
sample buffer for 10 minutes at 21oC and 40minutes at 37oC. Eluted biotinylated proteins were
then collected through centrifugation at 8000 rpm for 2 minutes. Eluted biotinylated proteins
were subjected to western blot analysis to determine the level of cell surface DAT.
For western blot analysis, both isolated biotinylated proteins and total lysates were
separated on 8% acrylamide gel and then transferred to nitrocellulose membranes. Cell surface
DAT (biotinylated) and total DAT were probed on membrane using rabbit anti-rat DAT
polyclonal primary antibody and anti-rabbit secondary antibody conjugated with horseradish
peroxidase. Blots were developed using Super Signal West Pico Chemiluminescent Substrate
detection reagents from Pierce. Chemiluminescent signals were captured by Geliance 600
imaging system (Perkin Elmer, Shelton, CT) and analyzed by GeneTools software (Syngene,
Frederick, MD). The integrated density values (IDV) of biotinylated DAT from western blot
images were normalized with the IDV of the corresponding total DAT western blot images. The
final data for all chemically treated groups were expressed as percentage of PBS control data.
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2.5 Immunocytochemistry
In order to visualize the distribution of DAT on the surface of PC12 cells,
immunocytochemistry was performed. Cells (1x104 cells per well) were seeded on poly-L-lysine
coated 4-well chamber slides on the day before chemical treatments. Cells were then treated with
mercuric chloride solution (0.2-1.0ppm) for either 30 minutes or 1 hour.
After chemical treatments, cells were washed with PBS three times and then fixed with
3.7% formaldehyde for 15 minutes at room temperature. Cells were rinsed with PBS and then
incubated with Image-iTFX (Thermo Fisher ScientificTM) signal enhancer for 30 minutes at room
temperature. After PBS wash, the cells were blocked with 1% BSA in PBS/0.5% Tween 20 (1%
BSA-PBS) for 1 hour at room temperature. Rabbit anti-DAT polyclonal primary antibody
(ThermoFisherScientificTM) (1:500 in 1% BSA-PBS) was applied to bind to DAT on the cells at
4oC for overnight. Cells were washed with PBS to remove primary antibody and goat anti-rabbit
secondary antibody conjugated to fluorescent dye Alexa Fluor 488(1:500 in 1% BSA-PBS) was
used to visualize DAT on the cells by binding to primary antibody at room temperature for 1
hour. The cells were then washed with PBS and pre-warmed mounting buffer (ProLong® Gold
antifade reagent (ThermoFisherScientificTM) was applied to each well and rested for 24 hours.
Then the slides were sealed with clear nail polish and analyzed under Nikon Eclipse E600
fluorescent microscope.
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2.6 Transfection
PC12 cells were transiently transfected with DAT mutant L368Q (a gift from Dr. Reith,
NYU School of Medicine, New York, NY). DAT mutant L368Q is known as a loss-function
mutant (Kurian et al., 2009). Transfection was performed using SuperFect TM transfection reagent
(Qiagen).
DAT mutant L368Q was mixed with SuperFectTM in a ratio of 1 µg DNA to 2 µl
transfection reagent according to the manufacturer’s protocol. The mixtures were added to PC12
cells grown on six-well plates in 0.6 mL of serum free DMEM. The cells were incubated with
the transfection mixtures for 3 hours at 37°C in humidified air containing 5% CO2. The
transfection mixtures were removed and replaced with 1 mL of DMEM containing 10% horse
serum and 5% FBS after cells were washed twice with PBS. The cells were incubated for
additional 24 hours at 37°C in humidified air containing 5% CO2 prior to chemical treatments.

2.7 Statistics
All experiments were performed at least in triplicate, and results are reported as means
±SEM. Statistical significance was determined using student’s t-test (p<0.05, with control at
100%).
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3. Results
3.1 PC12 cell viability in response to HgCl2 with or without MPP+
In order to evaluate the effect of HgCl2 on parkinsonian toxicant MPP+-induced
cytotoxicity, the toxicity of HgCl2 with or without 0.1 mM MPP+ co-treatment for 4 hours was
evaluated via MTT assay. Toxicity was observed to be concentration dependent with higher
concentrations of HgCl2 resulting in lower cell viability (Figure 1). Cells treated with 0.1 mM
MPP+ alone did not show any cytotoxic effect. When cells were treated with both MPP+ and
HgCl2, there was generally lower cell viability as compared withHgCl2 alone. At the 0.5
ppm HgCl2 concentration, a significant potentiation effect on MPP+ toxicity was seen which
resulted in a greater increase in cellular toxicity. This potentiation effect was not observed in the
cells treated with MPP+ and HgCl2 at concentrations that were lower (0.02 ppm and 0.2 ppm) or
higher (1.0 ppm and 2.0 ppm) than 0.5 ppm (Figure 1).

HgCl2

100

HgCl2 + MPP+

80

*

60
40
20
0

PBS
MPP+

Cell Viability
(percentage of control)

120

0.0

0.02

0.2

0.5

1.0

2.0

HgCl2 (ppm)

Figure 1 Effect of HgCl2 on the viability of PC12 cells incubated in the presence or absence of (0.1 mM) MPP +.
Cell viability was measured by MTT assay. Following 4 hours of chemical treatment, cell viability decreased in a
dose dependent manner with increasing HgCl2 concentration. Co-treatment of cells with 0.5 ppm HgCl2 and 0.1
mM MPP+ resulted in a significant potentiation of cytotoxicity (*p < 0.01). Data were normalized to control with
control as 100% cell viability. Data was obtained from 4 different experiments.
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These results showed that at the 0.5 ppm HgCl2 treatment concentration, some cellular
changes could have occurred which have the ability to enhance the toxicity of MPP +. The
mechanism resulting in the potentiation of toxicity observed at the 0.5 ppm HgCl2 treatment dose
when MPP+ was co-treated was further investigated as possibly resulting from the mechanism of
toxicity of MPP+. One of possible toxic mechanisms is via dopamine transporter. MPP+ requires
entry into the neuron via the use of a transporter, specifically the dopamine transporter prior to
causing neurotoxicity (Przedborski & Vila, 2001).

3.2 Cell surface expression of dopamine transporter in response to HgCl2
MPP+ is a well-known parkinsonian toxicant and is specifically transported into
dopaminergic neurons by dopamine transporter (DAT). Once inside the cells, MPP+ is mainly
accumulated in mitochondria and inhibits mitochondrial respiratory chain complex I (Nicklas,
Vyas, & Heikkila , 1985; Schildknecht et al., 2015). The cause of the potentiation of toxicity of
0.1 mM MPP+ when combined with 0.5 ppm HgCl2 in PC12 cells was investigated as possibly
being due to an alteration of the cell surface expression of dopamine transporter. Entry into the
cell is an essential step in order for MPP+ to exert its neurotoxic effects on the mitochondria
electron transport chain leading to cell death (Przedborski & Vila, 2001). The expression of the
dopamine transporter on the surface of the cells following HgCl2 exposure was investigated
using western blot analysis (Figure 2).
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Figure 2 Western blot analysis of the effect of HgCl2 on surface DAT expression following 30 or 60 minutes
exposure. (A) Western blot representative image; (B) Densitometric quantification of the DAT expression
following 30 min HgCl2 exposure (C) Densitometric quantification of DAT expression following 60 min exposure.
Integrated density values of surface DAT from western blot analysis was normalized to PBS control. The relative
expression of surface DAT in the PBS control group was taken as 1.
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Cells were exposed to HgCl2 for 0.2-2.0 ppm for 30 or 60 minutes. Control cells were
treated with PBS only. After chemical treatments, cell surface proteins were labeled with biotin
and isolated for western blot analysis. The results obtained from western blot analysis showed
that HgCl2 has a transient effect on the expression of cell surface dopamine transporter in PC12
cells (Figure 2). This trend was observed for both the 30 and 60 minutes HgCl 2 exposure times.
When PC12 cells were exposed to HgCl2 for 30 minutes, the maximum expression of cell surface
dopamine transporter was seen in cells treated with 1.0 ppm HgCl2. When PC12 cells exposed to
HgCl2 for 60 minutes, the maximum expression of cell surface dopamine transporter was
observed in cells treated with 0.5 ppm HgCl2.

3.3 Localization of dopamine transporter in response to HgCl2 exposure
The distribution of DAT on the surface of the cell following mercury exposure was
observed via cell surface DAT immunocytochemistry. The DAT distribution on the cell
membrane was seen to be denser for the 0.5ppm HgCl2 (Figure 3C) and 1.0 ppm (Figure 3D)
exposed cell groups than the control PBS group (Figure 3A). Slight scattering of fluorescent
DAT signal was seen in cells treated with 1.0 ppm HgCl2 (Figure 3D) when compared to control
PBS group (Figure 3A). No obvious change in the DAT expression was observed in the cells
treated with 0.2 ppm HgCl2 (Figure 3B) as compared with cells treated with PBS (Figure 3A).
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A

PBS

B

0.2 ppm HgCl2

C

D

0.5 ppm HgCl2

1.0 ppm HgCl2

Figure 3 Immunocytochemical images of surface DAT in PC12 cells exposed to different concentrations of HgCl 2
for 30 minutes. (A) PBS control; (B) 0.2 ppm HgCl 2; (C) 0.5 ppm HgCl2; (D) 1.0 ppm HgCl2. No increase in
surface DAT expression was observed in cells treated with 0.2 ppm HgCl 2 when compared to the cells treated with
PBS. Increase in cell surface DAT expression was observed in cells treated with 0.5 ppm and 1.0 ppm HgCl2.

3.4 The potentiation effect of HgCl2 on MPP+ triggered cytotoxicity was diminished in
PC12 with dysfunctional DAT.
To elucidate whether the potentiation effect trigged by HgCl2 on MPP+ triggered
cytotoxicity involves DAT, PC12 cells were transiently transfected to express null DAT
mutation (L368Q). The DAT L368Q cells were then treated with HgCl2 alone and 0.1mM MPP+
combined with HgCl2. The potentiation of toxicity previously observed with PC12 cells
containing functional DAT when treated with 0.5 ppm HgCl2 and 0.1mM MPP+ (Figure 1) was
not observed with same treatment for the DAT L368Q cells (Figure 4). At all HgCl 2 exposure
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concentrations, when treatment included MPP+, toxicity in the DAT L368Q cells was similar to
that of treatment of cells with HgCl2 alone (Figure 4). The significant potentiation effect of
HgCl2 at 0.5 ppm on MPP+ induced cytotoxicity was diminished when there was no functional

Cell Viability (percent of control)

DAT expressed.

120
HgCl2
HgCl2 + MPP+

100
80
60
40

20
0
0

0.2

0.5

1

2

HgCl2 (ppm)

Figure 4 Effect of HgCl2 on cell viability incubated in the presence or absence of (0.1 mM) MPP + in PC12 cells
transiently transfected to express null DAT mutant (L368Q). Cell viability was measured by MTT assay.
Following 4hours of chemical treatment, cell viability decreased in a dose dependent manner with increasing
HgCl2 concentration. With DAT L368Q mutant, the potentiation effect of 0.5 ppm HgCl 2 on MPP+ triggered
cytotoxicity observed in Figure 1 was diminished. Data were normalized to percent of control. Data was obtained
from 4 different experiments.

4. Discussion
The dopamine transporter (DAT) is important to limit the neurotransmission of dopamine
in the dopaminergic neuronal cells. Thus, drugs and toxins that target DAT can result in
dysfunction in the dopamine-signaling pathway. MPP+ is a known parkinsonian toxicant that
uses DAT to enter into the neuron to cause cell death. In this case, changes in the expression or
function DAT would result in an alteration of toxicity from agents such as MPP + that use it as a
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means of entry into the cell. Studies (Bourdineaud, Redwood, & Bernard, 2011; Lin, Liou,
Hsiech, Ku, & Tsai, 2011; Caudle, Guillot, Lazo, & Miller, 2012) suggest that exposure to
mercury can have substantial impact on the normal functioning of the nigrostriatal dopaminergic
system. Mercuric chloride has been shown to increase binding of radioligands to DAT in
membrane and whole cell suspensions (Schweri, 1994; Wu et al., 1997). While binding of
radioligands was increased, the effect on the expression and activity of DAT on the cell surfaces
was not explored. Other researchers have found that exposure to mercuric chloride did not
significant change in surface DAT density (Wallace & Hood, 2018).
In this study cell viability in response to mercury exposure was analyzed via MTT assay.
As expected mercuric chloride was observed to result in increasing cell death with increase in
concentration (Figure 1). Wallace & Hood (2018) also observed the decreased cell viability
following HgCl2 treatment. However, they found the significant decrease in cell viability only
after 48-hour exposure with 10 µM HgCl2 (2 ppm) in N2A cells. In this study 4 hours exposure
to 2 ppm HgCl2 caused cell viability decrease by 15% (Figure 1). The discrepancy in toxicity
could be due to several different reasons. First, the cytotoxicity assay Wallace & Hood (2018)
conduced was the lactate dehydrogenase leakage assay (LDH) assay. Principle of the LDH assay
is that when the cell membranes are damaged, LDH from the cytosol is released into the cell
culture media indicating plasma membrane damage (Kumar, Nagarajan, & Uchil, 2018). In
comparison, in this study, the MTT cytotoxicity assay conducted monitors mitochondrial
activity. As such, the MTT assay is much more sensitive in detecting cytotoxicity than the LDH
assay (Fotakis & Timbrell, 2006). Secondly, the basal p53 tumor suppressor expression in PC12
cells is lower than in N2A cells (Kuenzi, Kiefer, Koryakina, & Hamburger, 2008). The cytotoxic
signaling pathway triggered by HgCl2 could be different between two cell lines due to the
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differences in the basal p53 expressions. When the cells were additionally treated with MPP +, it
was observed that with 0.5 ppm HgCl2 there was a further decrease in cell viability compared to
when the cells were treated with HgCl2 alone (Figure 1). This potentiation effect of HgCl2 in
MPP+ induced cytotoxicity could be due to the changes in DAT expression due to the toxin's use
of the transporter as a means of entry into the cell. The surface expression of DAT in response to
HgCl2 was explored using western blot analysis and visualized by using immunocytochemistry.
Data obtained from western blot analysis indicated that the expression of DAT increased
transiently with increase of HgCl2 treatment concentration (Figure 2B/C). DAT had the maxima
expression at 0.5 and 1.0 ppm HgCl2 concentration for the 30 and 60 minutes exposures
respectively (Figure 2B/C).This increase was also observed visually on the surface of the cell via
immunocytochemical analysis. Agreeing with the increase in expression of the surface DAT seen
with western blot, there was a maximal intensity of DAT fluorescence signal observed at 0.5
ppm HgCl2 exposure concentration that decreased at higher mercury concentration (Figure 3).
Wallace & Hood (2018) showed the density of DAT on cell surface was not significantly
changed after 10 µM of HgCl2 for 72 hours exposure, but the functionality of DAT in N2A cells
treated with 10 µM of HgCl2 for 72 hours was increased. The N2A cells co-treated with heavy
metals and cocaine or methamphetamine caused further increases in the density of DAT on cell
surface. These authors suggested that low doses of heavy metals, such as Hg, may increase the
risk of exaggerated response to low doses of psychostimulants via altered DA
neurotransmission/turnover. In this study, we demonstrated that lower HgCl2 dosages and shorter
exposure times increased the density of DAT on PC12 cells. Previous research has suggested that
possible increase in DAT may be due to homeostatic response of the cell to maintain stable
synaptic DA levels as a result of reduction in function of DAT following Hg toxicity (Wu et al.
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1997; Wallace & Hood, 2018). Hg can attack thiol groups in the DAT disulfide bridge resulting
in abnormal function (Wallace & Hood, 2018). This may explain the increase of DAT expression
as the cell's response to the compromised function of the DAT as a result of Hg attack. Increase
in DAT expression and increase in functionality may result in similar increase of sensitivity to
psychostimulants such as that seen with heavy metal Pb and Mn exposure (Jones & Miller,
2008).
The involvement of the dopamine transporter in the potentiation of MPP+ induced
cytotoxicity was confirmed via identical chemical treatment of transfected PC12 cells containing
nonfunctional DAT mutant, DAT L368Q. DAT L368Q is known as a loss-of-function DAT
associated with infantile parkinsonism dystonia in humans (Kurian et al., 2009) with mutation at
L368 of the DAT. Cytotoxicity MTT assay showed that the potentiated decrease in cell viability
seen when HgCl2 was combined with MPP+ in the normal functional DAT cells was not
observed in DAT L368Q transfected cells at the 0.5 ppm HgCl2 treatment concentration. This
result indicated that functional DAT is necessary for the observed HgCl2 triggered potentiation
on MPP+ induced cytotoxicity.
In summary, mercury chloride enhanced the toxicity of parkinsonian toxicant MPP+ by
increasing the cell surface expression of DAT. The potentiation effect was seen to be dosedependent. The increase in cell surface expression of DAT as a result of mercury exposure was
transient and also correlated to dosage and time of exposure. This was a novel finding about the
expression of cell surface DAT in mercury neurotoxicity. Further implication regarding the
increase of expression of DAT and DA turnover would be possible increase of sensitivity to
psychostimulants similar to that seen with Pb and Mn exposure (Jones & Miller, 2008). As a
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result, low dose mercury exposure may result in altered sensitivity to drugs that affect the
dopaminergic system.
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